The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Belamaf plus DRd in TI patients with newly diagnosed myeloma: the Phase I/II BelaDRd study
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, provides insight into the BelaDRd trial (EUCT-2024-515634-32), a Phase I/II open-label study that evaluated a quadruplet combination of belantamab mafodotin, daratumumab, lenalidomide, and dexamethasone in transplant-ineligible (TI) patients with newly diagnosed multiple myeloma (MM). Dr Dimopoulos highlights the promising activity of the combination regimen and notes that it was well tolerated, with few discontinuation events, despite the older age and frailty of many patients. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The Belantamab-Daratumumab-Lenalidomide-dexamethasone phase 1-2 study has been developed in our center in an attempt to investigate this quadruplet combination in the frontline setting of elderly, non-transplant eligible patients. So we performed a phase 1/2 study. We have included approximately 40 patients and we have seen that we can achieve complete responses in the overwhelming majority of the patients, including MRD negative status in about 60% of the patients...
The Belantamab-Daratumumab-Lenalidomide-dexamethasone phase 1-2 study has been developed in our center in an attempt to investigate this quadruplet combination in the frontline setting of elderly, non-transplant eligible patients. So we performed a phase 1/2 study. We have included approximately 40 patients and we have seen that we can achieve complete responses in the overwhelming majority of the patients, including MRD negative status in about 60% of the patients. The regimen was very well tolerated because Belantamab mafodotin was given every three months as an IV injection and actually the dose was adjusted and the dose interval was adjusted according to the ocular toxicity. Despite the fact that our patients were older and several of them were unfit or even frail, we were able to have very few discontinuation events. And as I said, excellent MRD negative and very long PFS data so far. So we’re very encouraged that this is an active combination that warrants further investigation in the frontline therapy of patients with myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
